DOCSLIB.ORG

Evaluating the Role of CD200 Signalling in Renal Cell Carcinoma Immune Evasion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evaluating the Role of CD200 Signalling in Renal Cell Carcinoma Immune Evasion Evaluating the role of CD200 signalling in renal cell carcinoma immune evasion Elise Rees Thesis submitted for the award of PhD 31 st March 2020 Abstract CD200 is a transmembrane protein with known immunosuppressive properties. This ligand functions by engaging its receptor, CD200R, found on many immune cell populations. Overexpression of CD200 has been linked to a number of cancer types as a mechanism of immune evasion. An in-human study has demonstrated a clinical benefit of targeting this ligand, which has led to the interest in identifying other cancer types that may also benefit from CD200 checkpoint inhibition. The main aim of this project was to determine whether CD200 expression was a relevant therapeutic target in renal cell carcinoma (RCC). We demonstrated that CD200 is expressed at protein level across RCC subtypes, which we suggest originates from the cell of origin for this cancer type, the renal tubules. We characterised the impact of CD200 expression level on the immune infiltrate and demonstrated a significant reduction in the presence of helper T cells, whilst NK cell presence remained relatively unaffected and suggestive of NK cell dysfunction. Using cell culture assays, we demonstrate that tumour CD200 expression inhibited CD200R+ NK cell function, both the cytotoxic and effector activity, which led to a diminished ability to kill CD200 expressing target cells. Blocking the CD200 signal was sufficient to restore NK cell activity in vitro and restore tumour cell killing. In addition to providing an inhibitory signal to interacting NK cells, the engagement of CD200R by its ligand induced the up-regulation of the Fas death receptor pathway, which resulted in apoptosis of the NK cell via induction of the caspase 8-dependent extrinsic pathway. These findings reveal a novel immunosuppressive mechanism by which both NK cell activity and presence at the tumour bed is inhibited. This study provides evidence that suggests that some RCC patients may benefit from CD200 immune checkpoint inhibition. ii Acknowledgements Firstly, I would express my heartfelt thanks to my supervisor, Dr Girish Patel, for giving me this opportunity and for his continual help, encouragement and guidance throughout my PhD. Secondly, many thanks go to my second supervisor, Dr Richard Clarkson, for his support and advice. I am very grateful to all the members of the GKP lab group, both past and present, for their help and advice as well as their friendship and support. I am also thankful the support I received from members of The European Cancer Stem Cell Research Institute. I would also like to thank KESSII and the European Social Fund, who made this project possible as well as member of the local health board that gave me an insight into the clinical side of cancer. Finally, I would like to thank my family and friends for their ongoing support throughout my time at university. iii List of Abbreviations AD - Alzheimer's disease ADAMs - Membrane-anchored proteins disintegrin and metalloprotease domains AJCC - American joint committee on cancer AML - Acute myeloid leukaemia AP-3 - Adaptor protein 3 APC - Antigen presenting cells BAP1 - BRCA1 associated protein-1 BCC - Basal cell carcinoma ccRCC - Clear cell renal cell carcinoma CD200 - Cluster of differentiation 200 CD200R - CD200 receptor CD200tg - CD200 transgene cFLIP - caspase 8-like inhibitory protein chRCC - Chromophobe renal cell carcinoma CIA - Collagen-induced arthritis CLL - Chronic lymphocytic leukaemia CLP - Common lymphoid progenitor CNS - Central nervous system CRs - Completed responses CSCC - Cutaneous squamous cell carcinoma CSCs - Cancer stem cells cSMAC - Central supramolecular activation complex CTL - Cytotoxic T cell CTLA-4 - Cytotoxic T lymphocyte-associated Antigen 4 DCs - Dendritic cells DD - Death domain DP - Double positive thymocytes DR - Death receptor dSMAC - Distal supramolecular activation complex ERKs - Extracellular signal-regulated kinases F-actin - Filamentous actin v FADD - FAS-associated death domain FasL - Fas ligand FHL3 - Familial haemophagocytic lymphohistiocytosis subset 3 FoxP3 - Forkhead box P3 GATA3 - GATA-binding protein HCC - Hepatocellular carcinoma HIF1-a - Hypoxia-inducible factor 1 alpha HIF2-a - Hypoxia-inducible factor 2 alpha HNSCC - Head and neck squamous cell carcinoma HPS2 - Hermansky-Pudlak syndrome subset 2 HSCs - Hematopoietic stem cells IFNg - Interferon gamma I - Immunoglobulin ISF - Ig superfamily IL- - Interleukin iNK - Immature NK cell IPEX - Immune Dysregulation Polyendocrinopathy, Enteropathy, X-linked disease IS - Immunological synapse ITAM - Immunoreceptor tyrosine-based activation motif ITIM - Immunoreceptor tyrosine-based inhibition motif iTres - Induced Tregs KIRs - Killer immunoglobulin-like receptors LAG-3 - Lymphocyte activation gene-3 MAPKs - Mitogen-activated protein kinases MDP - Macrophage-dendritic cell progenitor MHC - Major histocompatibility complex MPPs - Multipotent progenitors mRCC - Metastatic renal cell carcinoma MTOC - Microtubule organisation centre mTOR - Mammalian target of rapamycin mTORC - Mammalian target of rapamycin complex MZ - Marginal zone B cell vi NCR - Natural cytotoxicity receptor NK - Natural killer cells NKG2D - Natural-killer group 2, member D NSCLC - Non-small-cell lung cancer nTreg - Natural Tregs ORR - Overall response rate OS - Overall survival PBRM1 - Polybromo 1 PD-1 - Programmed cell death protein 1 PDGFB - Platelet-derived growth factor beta PFS - Progression free survival PI3K - Phosphatidylinositol-3-kinase PMBCL - Primary mediastinal B-cell lymphoma pRCC - Papillary renal cell carcinoma pSMAC - Peripheral supramolecular activation complex PTB - Phosphotyriosine-binding RCC - Renal cell carcinoma sCD200 - soluble form CD200 sFasL - Soluble fas ligand SHIP 1 - Lipid phosphatase SH2 domain-containing inositol-5-phosphatase SHP-1 - SRC homology-containing tyrosine phosphatase 1 SMAC - Supramolecular activation cluster SNAREs - Soluble N-ethylmaleimide-sensitive factor attachment protein receptors SP - Single positive thymocytes TCR - T cell receptor TGF - Transforming growth factor TIL – Tumour infiltrating lymphocyte TIM-3 - T cell immunoglobulin and mucin domain 3 TKI - Tyrosine kinase inhibitor TME - Tumour microenvironment TNF - Tumour necrosis factor TNFR - TNF-receptor vii TNM - Tumour-node-metastasis TRADD - TNFR-associated death domain TRAIL - TNF-related apoptosis-inducing ligand TRAIL-R - TNF-related apoptosis-inducing ligand receptor Tregs - Regulatory T cells VEGF - Vascular endothelial growth factor VEGFR - Vascular endothelial growth factor receptor VHL - Von Hippel-Lindau VISTA - V-domain immunoglobulin-containing suppressor of T-cell activation WAS - Wiskott-Aldrich syndrome WASp - Wiskott-Aldrich syndrome protein WT - Wild-type viii Table of Contents Chapter 1: Introduction 1.1 Hallmarks of cancer ……………………………………………………………………………..………….. 1 1.1.1 The tumour microenvironment …………………………………………………………..…………. 1 1.2 Cells of the immune system …………………………………………………………………….………. 2 1.2.1 Myeloid Lineage …………………………….………………………………………………………….…... 3 1.2.1.1 Granulocytes …………..……………………………...……………………………….…………..… 4 1.2.1.1.1 Neutrophils …………………………………………………...……………..……………...… 4 1.2.1.1.2 Basophils ……………….……………………………………………....………………….…… 4 1.2.1.1.3 Eosinophils ………………………………..………………….……….………………….……. 5 1.2.1.1.4 Mast Cells ……………………………………………………………...……………………..… 5 1.2.1.2 Macrophages …………………………………………………………………….….……………. 5 1.2.1.3 Dendritic Cells ……………………………………..………………………………...………….. 6 1.2.2 Lymphoid Lineage …………………………………………………………………………………….…….. 7 1.2.2.1 B Lymphocytes ……………………………………………………………………………………...... 7 1.2.2.2 T Lymphocytes ……………………………………………………………………………………..…. 8 1.2.2.2.1 CD4+ T cells ………………………………………………………………………….………….. 8 1.2.2.2.1a Th1 Differentiation ……………………………………………………………………….… 9 1.2.2.2.1b Th2 Differentiation ……………………………………………………………………..….. 9 1.2.2.2.1c Regulatory T cells ………………………………………………………………….………... 9 1.2.2.2.2 CD8+ T cells ………………………………………………………………………………..…... 10 1.2.2.2.3 Memory T cells ………………………………………………………………………………... 11 1.2.2.3 T cell Activation …………………………………………………………………………………….... 11 1.2.2.3.1 T cell receptor ……………………………………………………………………………….... 14 1.2.2.3.1a Stimulatory Receptors ……………………………………………………………….….. 14 1.2.2.3.1b Inhibitory Receptors ……………………………………………………………………... 14 1.2.2.4 Natural Killer Cells …………………………………………………………………………………... 17 1.2.2.4.1 NK cell development and maturation …………………………………………….... 17 1.2.2.4.2 NK cell subsets ……………………………………………………………………………….... 18 1.2.2.4.3 Regulation of NK cell activation …………………………………………………….….. 18 1.2.2.4.3a Inhibitory Receptors on NK cells …………………………………………………….. 19 1.2.2.4.3b Activating Receptors on NK cells ………………………………………..………….. 20 ix 1.2.3 NK cell activity ………………………………………………………………………………………….. 22 1.2.3.1 Cytotoxic Immune Response of NK cells ……………………………………………. 22 I. Formation of immunological synapse (IS) between target and NK cell and the reorganisation of the actin skeleton II. Polarisation of microtubule organisation centre (MTOC) and secretory lysosome toward lytic synapse III. Docking of secretory lysosome with the plasma membrane of NK cells IV. Fusion of secretory lysosome with the plasma membrane of target cells 1.2.3.1.1 Lytic Granules ……………………………………………………………………………….... 25 1.2.2.5.2a Perforin/Granzyme Apoptosis Pathway ……………………….....…….……… 25 1.2.2.5.2b Other contents of lytic granules ………………………………..………………….. 26 1.2.2.5.3 Death receptor-mediated apoptosis pathways ………………..……………… 26 1.2.2.5.4 Death receptor signalling
Load more

Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Platelets Impair Natural Killer Cell Reactivity and Function in Endometriosis Through Multiple Mechanisms
    Human Reproduction, Vol.32, No.4 pp. 794–810, 2017 Advanced Access publication on February 9, 2017 doi:10.1093/humrep/dex014 ORIGINAL ARTICLE Gynaecology Platelets impair natural killer cell reactivity and function in endometriosis through multiple mechanisms Yanbo Du, Xishi Liu, and Sun-Wei Guo* Shanghai Obstetrics and Gynecology Hospital, Fudan University Shanghai College of Medicine, 419 Fangxie Road, Shanghai 200011, China *Correspondence Address. Shanghai Obstetrics and Gynecology Hospital, Fudan University Shanghai College of Medicine, Shanghai 200011, China. Fax: 86-21-6345-5090; E-mail: [email protected] Submitted on October 28, 2016; resubmitted on December 27, 2016; accepted on January 13, 2017 STUDY QUESTION: Do platelets have any role in the reduced cytotoxicity of natural killer (NK) cells in endometriosis? SUMMARY ANSWER: Platelets impair NK cell reactivity and function in endometriosis through multiple mechanisms. WHAT IS KNOWN ALREADY: Platelets play an important role in the development of endometriosis, and platelet-derived transforming growth factor-β1 (TGF-β1) suppresses the expression of NK Group 2, Member D (NKG2D) on NK cells, resulting in reduced cytotoxicity in women with endometriosis. STUDY DESIGN SIZE, DURATION: Experiments on mice with induced endometriosis in which either platelets, NK cells or both were depleted and controls (none depleted). In vitro experiments with NK cells, platelets and, as target cells, endometriotic epithelial cell and endo- metrial stromal cell lines. PARTICIPANTS/MATERIALS SETTING METHODS: Immunohistochemistry analysis of ectopic endometrial tissues from mice with induced endometriosis receiving either platelet depletion (PD), NK cell depletion, or both or none. Immunofluorescence, flow cytometry and gene expression analysis for major histocompatibility complex class I (MHC-I) expression in target cells.
    [Show full text]
  • Deciphering the Transcriptional Switches of Innate Lymphoid Cell Programming: the Right Factors at the Right Time
    Genes and Immunity (2015) 16, 177–186 © 2015 Macmillan Publishers Limited All rights reserved 1466-4879/15 www.nature.com/gene REVIEW Deciphering the transcriptional switches of innate lymphoid cell programming: the right factors at the right time AWY Lim and ANJ McKenzie Innate lymphoid cells (ILCs) are increasingly recognised as an innate immune counterpart of adaptive T-helper (TH) cells. In addition to their similar effector cytokine production, there is a strong parallel between the transcription factors that control the differentiation of TH1, TH2 and TH17 cells and ILC groups 1, 2 and 3, respectively. Here, we review the transcriptional circuit that specifies the development of a common ILC progenitor and its subsequent programming into distinct ILC groups. Notch, GATA-3 (GATA-binding protein 3), Nfil3 (nuclear factor interleukin-3) and Id2 (inhibitor of DNA-binding 2) are identified as early factors that suppress B- and T-cell potentials and are turned on in favour of ILC commitment. Natural killer cells, which are the cytotoxic ILCs, develop along a pathway distinct from the rest of the helper-like ILCs that are derived from a common progenitor to all helper-like ILCs (CHILPs). PLZF− (promyelocytic leukaemia zinc-finger) CHILPs give rise to lymphoid tissue inducer cells, while PLZF+ CHILPs have multilineage potential and could give rise to ILCs 1, 2 and 3. Such lineage specificity is dictated by the controlled expression of T-bet (T-box expressed in T cells), RORα (retinoic acid receptor-related orphan nuclear receptor-α), RORγt (retinoic acid receptor- related orphan nuclear receptor-γt) and AHR (aryl hydrocarbon receptor).
    [Show full text]
  • Flow Reagents Single Color Antibodies CD Chart
    CD CHART CD N° Alternative Name CD N° Alternative Name CD N° Alternative Name Beckman Coulter Clone Beckman Coulter Clone Beckman Coulter Clone T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells CD1a T6, R4, HTA1 Act p n n p n n S l CD99 MIC2 gene product, E2 p p p CD223 LAG-3 (Lymphocyte activation gene 3) Act n Act p n CD1b R1 Act p n n p n n S CD99R restricted CD99 p p CD224 GGT (γ-glutamyl transferase) p p p p p p CD1c R7, M241 Act S n n p n n S l CD100 SEMA4D (semaphorin 4D) p Low p p p n n CD225 Leu13, interferon induced transmembrane protein 1 (IFITM1). p p p p p CD1d R3 Act S n n Low n n S Intest CD101 V7, P126 Act n p n p n n p CD226 DNAM-1, PTA-1 Act n Act Act Act n p n CD1e R2 n n n n S CD102 ICAM-2 (intercellular adhesion molecule-2) p p n p Folli p CD227 MUC1, mucin 1, episialin, PUM, PEM, EMA, DF3, H23 Act p CD2 T11; Tp50; sheep red blood cell (SRBC) receptor; LFA-2 p S n p n n l CD103 HML-1 (human mucosal lymphocytes antigen 1), integrin aE chain S n n n n n n n l CD228 Melanotransferrin (MT), p97 p p CD3 T3, CD3 complex p n n n n n n n n n l CD104 integrin b4 chain; TSP-1180 n n n n n n n p p CD229 Ly9, T-lymphocyte surface antigen p p n p n
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • Immunology Focus Summer | 2006 Immunology FOCUS
    R&D Systems Immunology Focus summer | 2006 Immunology FOCUS Inside page 2 Signal Transduction: Kinase & Phosphatase Reagents page 3 Lectin Family page 4 Regulatory T Cells page 5 Natural Killer Cells page 6 Innate Immunity & Dendritic Cells page 7 Co-Stimulation/-Inhibition The B7 Family & Associated Molecules page 8 Proteome Profiler™ Phospho-Immunoreceptor Array ITAM/ITIM-Associated Receptors www.RnDSystems.com Please visit our website @ www.RnDSystems.com for product information and past issues of the Focus Newsletter: Cancer, Neuroscience, Cell Biology, and more. Quality | Selec tion | Pe rformance | Result s Cancer Development Endocrinology Immunology Neuroscience Proteases Stem Cells Signal Transduction: Kinase & Phosphatase Reagents Co-inhibitory PD-L2/PD-1 signaling & SHP-2 phosphatase KINASE & PHOSPHATASE RESEARCH REAGENTS Regulation of MAP kinase (MAPK) signaling Kinases Phosphatases pathways is critical for T cell development, MOLECULE ANTIBODIES ELISAs/ASSAYS MOLECULE ANTIBODIES ELISAs/ASSAYS activation, differentiation, and death. MAPKs Akt Family H M R H M R Alkaline Phosphatase* H M R are activated by the dual phosphorylation of threonine and tyrosine residues resulting in AMPK H M R Calcineurin A, B H M R subsequent transcription factor activation. ATM H M R H CD45 H M H M The MAPK signaling pathway in T cells can be CaM Kinase II Ms CDC25A, B* H M R triggered by cytokines, growth factors, and CDC2 H M R DARPP-32 M R ligands for transmembrane receptors. Chk1, 2 H M R H M R DEP-1/CD148* H M R H Ligation of the T cell receptor (TCR)/CD3 ERK1, 2 H M R H M R LAR H M R complex results in rapid activation of PI 3- kinase, which leads to Akt and MAPK ERK3 H Lyp H activation.
    [Show full text]
  • NK Cells: Receptors and Functions Eric Vivier and Sophie Ugolini
    NK cells: receptors and functions Eric Vivier and Sophie Ugolini Natural killer (NK) cells were identified in 1975 as lymphocytes of the innate many processes that were originally restricted to adaptive immunity, such immune system that can kill tumour cells. Since then, NK cells have been as priming, education and memory, are now known to occur in NK cells. shown to kill an array of ‘stressed’ cells and secrete cytokines that Indeed, NK cells undergo sophisticated processes of adaptation that allow participate in shaping adaptive immune responses. A key feature of NK cells them to be tuned to their environment. There is also a growing interest in resides in their capacity to distinguish stressed cells (such as tumour cells, manipulating NK cells in innovative therapeutic settings. For example, the infected cells and damaged cells) from normal cells. Although NK cells are understanding of NK cell inhibition by MHC class I-specific receptors has generally considered to be components of early innate immune defence, prompted the design of innovative anticancer therapies. The NK cell detection system includes numerous receptors, Key receptors on human NK cells the engagement of which dictates the quality and intensity Inhibitory receptors Activating receptors, adhesion molecules or co-stimulatory molecules of the NK cell response. NK cells use inhibitory receptors to gauge the absence of constitutively expressed self molecules Target cell Nectin 2 SLAMF7 Sialic CLEC2D (CD112, PVRL2) NECL2 L-selectin NECL5 AICL NTB-A (CRACC, on susceptible target cells. As a consequence, NK cells can Receptors for MHC class I and class I-Iike molecules B7-H6 acid Cadherins (LLT1) CMV pp65 NECL5 (CADM1) (CD62L) (CD155, PVR) (CLEC2B) CEACAM1 (SLAMF6) CS1, CD319) recognize ‘missing self’ on haematopoietic cells.
    [Show full text]
  • Human CD Marker Chart Reviewed by HLDA1 Bdbiosciences.Com/Cdmarkers
    BD Biosciences Human CD Marker Chart Reviewed by HLDA1 bdbiosciences.com/cdmarkers 23-12399-01 CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD1a R4, T6, Leu6, HTA1 b-2-Microglobulin, CD74 + + + – + – – – CD93 C1QR1,C1qRP, MXRA4, C1qR(P), Dj737e23.1, GR11 – – – – – + + – – + – CD220 Insulin receptor (INSR), IR Insulin, IGF-2 + + + + + + + + + Insulin-like growth factor 1 receptor (IGF1R), IGF-1R, type I IGF receptor (IGF-IR), CD1b R1, T6m Leu6 b-2-Microglobulin + + + – + – – – CD94 KLRD1, Kp43 HLA class I, NKG2-A, p39 + – + – – – – – – CD221 Insulin-like growth factor 1 (IGF-I), IGF-II, Insulin JTK13 + + + + + + + + + CD1c M241, R7, T6, Leu6, BDCA1 b-2-Microglobulin + + + – + – – – CD178, FASLG, APO-1, FAS, TNFRSF6, CD95L, APT1LG1, APT1, FAS1, FASTM, CD95 CD178 (Fas ligand) + + + + + – – IGF-II, TGF-b latency-associated peptide (LAP), Proliferin, Prorenin, Plasminogen, ALPS1A, TNFSF6, FASL Cation-independent mannose-6-phosphate receptor (M6P-R, CIM6PR, CIMPR, CI- CD1d R3G1, R3 b-2-Microglobulin, MHC II CD222 Leukemia
    [Show full text]
  • Engineered Type 1 Regulatory T Cells Designed for Clinical Use Kill Primary
    ARTICLE Acute Myeloid Leukemia Engineered type 1 regulatory T cells designed Ferrata Storti Foundation for clinical use kill primary pediatric acute myeloid leukemia cells Brandon Cieniewicz,1* Molly Javier Uyeda,1,2* Ping (Pauline) Chen,1 Ece Canan Sayitoglu,1 Jeffrey Mao-Hwa Liu,1 Grazia Andolfi,3 Katharine Greenthal,1 Alice Bertaina,1,4 Silvia Gregori,3 Rosa Bacchetta,1,4 Norman James Lacayo,1 Alma-Martina Cepika1,4# and Maria Grazia Roncarolo1,2,4# Haematologica 2021 Volume 106(10):2588-2597 1Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 2Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 3San Raffaele Telethon Institute for Gene Therapy, Milan, Italy and 4Center for Definitive and Curative Medicine, Stanford School of Medicine, Stanford, CA, USA *BC and MJU contributed equally as co-first authors #AMC and MGR contributed equally as co-senior authors ABSTRACT ype 1 regulatory (Tr1) T cells induced by enforced expression of interleukin-10 (LV-10) are being developed as a novel treatment for Tchemotherapy-resistant myeloid leukemias. In vivo, LV-10 cells do not cause graft-versus-host disease while mediating graft-versus-leukemia effect against adult acute myeloid leukemia (AML). Since pediatric AML (pAML) and adult AML are different on a genetic and epigenetic level, we investigate herein whether LV-10 cells also efficiently kill pAML cells. We show that the majority of primary pAML are killed by LV-10 cells, with different levels of sensitivity to killing. Transcriptionally, pAML sensitive to LV-10 killing expressed a myeloid maturation signature.
    [Show full text]
  • 1 Novel Expression Signatures Identified by Transcriptional Analysis
    ARD Online First, published on October 7, 2009 as 10.1136/ard.2009.108043 Ann Rheum Dis: first published as 10.1136/ard.2009.108043 on 7 October 2009. Downloaded from Novel expression signatures identified by transcriptional analysis of separated leukocyte subsets in SLE and vasculitis 1Paul A Lyons, 1Eoin F McKinney, 1Tim F Rayner, 1Alexander Hatton, 1Hayley B Woffendin, 1Maria Koukoulaki, 2Thomas C Freeman, 1David RW Jayne, 1Afzal N Chaudhry, and 1Kenneth GC Smith. 1Cambridge Institute for Medical Research and Department of Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK 2Roslin Institute, University of Edinburgh, Roslin, Midlothian, EH25 9PS, UK Correspondence should be addressed to Dr Paul Lyons or Prof Kenneth Smith, Department of Medicine, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK. Telephone: +44 1223 762642, Fax: +44 1223 762640, E-mail: [email protected] or [email protected] Key words: Gene expression, autoimmune disease, SLE, vasculitis Word count: 2,906 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Annals of the Rheumatic Diseases and any other BMJPGL products to exploit all subsidiary rights, as set out in their licence (http://ard.bmj.com/ifora/licence.pdf). http://ard.bmj.com/ on September 29, 2021 by guest. Protected copyright. 1 Copyright Article author (or their employer) 2009.
    [Show full text]
  • Mechanisms of Activation of Innate-Like Intraepithelial T Lymphocytes
    www.nature.com/mi REVIEW ARTICLE OPEN Mechanisms of activation of innate-like intraepithelial T lymphocytes Maud Vandereyken1, Olivia J. James1 and Mahima Swamy1 Intraepithelial T lymphocytes (T-IEL) contain subsets of innate-like T cells that evoke innate and adaptive immune responses to provide rapid protection at epithelial barrier sites. In the intestine, T-IEL express variable T cell antigen receptors (TCR), with unknown antigen specificities. Intriguingly, they also express multiple inhibitory receptors, many of which are normally found on exhausted or antigen-experienced T cells. This pattern suggests that T-IEL are antigen-experienced, yet it is not clear where, and in what context, T-IEL encounter TCR ligands. We review recent evidence indicating TCR antigens for intestinal innate-like T-IEL are found on thymic or intestinal epithelium, driving agonist selection of T-IEL. We explore the contributions of the TCR and various co- stimulatory and co-inhibitory receptors in activating T-IEL effector functions. The balance between inhibitory and activating signals may be key to keeping these highly cytotoxic, rapidly activated cells in check, and key to harnessing their immune surveillance potential. Mucosal Immunology (2020) 13:721–731; https://doi.org/10.1038/s41385-020-0294-6 1234567890();,: INTRODUCTION types within the epithelium may be blurred, in order to permit IEL Intestinal intraepithelial T lymphocytes (T-IEL) constitute the to rapidly respond to changes at the epithelium. largest T cell compartment in the body, with a ratio
    [Show full text]
  • Reviewed by HLDA1
    Human CD Marker Chart Reviewed by HLDA1 T Cell Key Markers CD3 CD4 CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD8 CD1a R4, T6, Leu6, HTA1 b-2-Microglobulin, CD74 + + + – + – – – CD74 DHLAG, HLADG, Ia-g, li, invariant chain HLA-DR, CD44 + + + + + + CD158g KIR2DS5 + + CD248 TEM1, Endosialin, CD164L1, MGC119478, MGC119479 Collagen I/IV Fibronectin + ST6GAL1, MGC48859, SIAT1, ST6GALL, ST6N, ST6 b-Galactosamide a-2,6-sialyl- CD1b R1, T6m Leu6 b-2-Microglobulin + + + – + – – – CD75 CD22 CD158h KIR2DS1, p50.1 HLA-C + + CD249 APA, gp160, EAP, ENPEP + + tranferase, Sialo-masked lactosamine, Carbohydrate of a2,6 sialyltransferase + – – + – – + – – CD1c M241, R7, T6, Leu6, BDCA1 b-2-Microglobulin + + + – + – – – CD75S a2,6 Sialylated lactosamine CD22 (proposed) + + – – + + – + + + CD158i KIR2DS4, p50.3 HLA-C + – + CD252 TNFSF4,
    [Show full text]